Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CareDx, Inc. CDNA

Healthcare  —  Diagnostics & Research
63.68 2.31 3.76% as of 25 Sep
Market cap
$3.2B
P/E
29.6×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

CareDx, Inc. (CDNA) Business Profile

Updated before January 2025

Company Overview

CareDx, Inc. (NASDAQ: CDNA) is a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established itself as a pioneer in the field of transplant diagnostics. The company was co-founded by Dr. Stephen Quake, a renowned scientist and innovator in the field of genomics. Over the years, CareDx has grown under the leadership of key executives, including its current CEO, Reginald Seeto, who has been instrumental in driving the company’s strategic vision and operational excellence.

CareDx’s mission is to improve the long-term outcomes of transplant patients by providing innovative diagnostic solutions and services. The company operates globally, with a strong presence in the United States, Europe, and other international markets. Its commitment to innovation and patient care has earned it a reputation as a trusted partner in the transplant community.

Core Business Segments

CareDx operates through several core business segments, each focused on addressing critical needs in the transplant ecosystem. These segments include:

1. Transplant Diagnostics

CareDx offers a range of diagnostic tests designed to monitor the health of transplant patients and detect potential complications early. Key products in this category include:

  • AlloSure®: A non-invasive blood test that measures donor-derived cell-free DNA (dd-cfDNA) to assess organ health and detect rejection in kidney transplant recipients.
  • AlloMap®: A gene expression profiling test used to monitor heart transplant recipients for signs of rejection.
  • AlloSeq®: A suite of next-generation sequencing (NGS) solutions for HLA typing and donor-recipient matching.

2. Digital Health Solutions

CareDx provides digital tools and platforms to enhance patient care and improve clinical workflows. These include:

  • CareDx Cloud: A comprehensive platform that integrates diagnostic data, electronic medical records (EMRs), and patient-reported outcomes to support personalized care.
  • Patient Apps: Mobile applications like AlloCare®, which empower transplant patients to manage their health and stay connected with their care teams.

3. Transplant Services

The company also offers laboratory services to support transplant centers and healthcare providers. These services include pre-transplant testing, post-transplant monitoring, and research support.

4. Research and Development

CareDx invests heavily in R&D to drive innovation and expand its product portfolio. The company collaborates with leading academic institutions, healthcare providers, and industry partners to develop new diagnostic solutions and improve existing ones.

Business Model

CareDx’s business model is centered around providing integrated solutions that combine advanced diagnostics, digital health tools, and laboratory services. The company generates revenue through the sale of its diagnostic tests, subscription fees for its digital health platforms, and fees for its laboratory services. By offering a comprehensive suite of solutions, CareDx aims to create value for patients, healthcare providers, and payers.

The company’s focus on precision medicine and personalized care enables it to address the unique needs of transplant patients. Its non-invasive diagnostic tests reduce the need for invasive biopsies, improving patient comfort and outcomes. Additionally, CareDx’s digital health solutions enhance care coordination and enable data-driven decision-making.

Strategic Direction

CareDx is committed to advancing the field of transplant medicine through innovation and collaboration. Key strategic priorities include:

  • Expanding Product Portfolio: The company is actively developing new diagnostic tests and digital health solutions to address unmet needs in the transplant community.
  • Global Expansion: CareDx is focused on increasing its presence in international markets, particularly in Europe and Asia.
  • Sustainability Goals: The company is dedicated to reducing its environmental footprint and promoting sustainable practices across its operations.
  • Partnerships and Collaborations: CareDx continues to collaborate with academic institutions, healthcare providers, and industry partners to drive innovation and improve patient outcomes.

Competitive Landscape

CareDx operates in a competitive market, facing competition from both established players and emerging companies. Key competitors include:

  • Natera, Inc.: A biotechnology company offering genetic testing and diagnostics, including solutions for transplant patients.
  • Thermo Fisher Scientific: A global leader in life sciences, providing a range of diagnostic and research tools.
  • Eurofins Scientific: A multinational group offering laboratory services and diagnostic solutions.
  • Immucor, Inc.: A company specializing in transfusion and transplantation diagnostics.

Despite the competition, CareDx differentiates itself through its focus on precision medicine, innovative product offerings, and strong relationships with the transplant community.

Risk Factors

CareDx faces several risks that could impact its business operations and financial performance. These include:

  • Market Dependence: The company relies heavily on the transplant market, which is subject to fluctuations in demand and regulatory changes.
  • Regulatory Risks: Changes in healthcare policies and regulations could affect the approval and adoption of CareDx’s products.
  • Supply Chain Disruptions: The company’s operations could be impacted by disruptions in the supply chain, particularly for critical raw materials and components.
  • Competition: Intense competition from established players and new entrants could affect CareDx’s market share and pricing power.
  • Technological Risks: Rapid advancements in technology could render CareDx’s products obsolete or less competitive.

Recent Developments

CareDx has made significant strides in recent years, including:

  • Launch of New Products: The company recently introduced AlloSure® Lung, a diagnostic test for lung transplant recipients, expanding its portfolio of non-invasive tests.
  • Strategic Partnerships: CareDx has entered into collaborations with leading healthcare providers and research institutions to advance transplant care.
  • Digital Health Innovations: The company continues to enhance its digital health platforms, integrating new features and capabilities to improve patient care.
  • Global Expansion: CareDx has expanded its operations in Europe and Asia, establishing new partnerships and increasing market penetration.

Investment Considerations

Investors considering CareDx should weigh the following strengths and risks:

Strengths

  • Market Leadership: CareDx is a leader in the transplant diagnostics market, with a strong brand and reputation.
  • Innovative Products: The company’s focus on precision medicine and non-invasive diagnostics sets it apart from competitors.
  • Growth Potential: CareDx is well-positioned to benefit from the growing demand for transplant diagnostics and personalized medicine.
  • Strong R&D Pipeline: The company’s commitment to innovation ensures a steady stream of new products and services.

Risks

  • Market Dependence: Heavy reliance on the transplant market could expose the company to fluctuations in demand.
  • Regulatory Challenges: Changes in healthcare policies and regulations could impact product approvals and adoption.
  • Competitive Pressure: Intense competition could affect market share and profitability.
  • Operational Risks: Supply chain disruptions and technological risks could impact business operations.

Conclusion

CareDx, Inc. is a pioneering company in the field of transplant diagnostics, offering innovative solutions that improve patient outcomes and enhance care delivery. With a strong focus on precision medicine, a robust product portfolio, and a commitment to innovation, CareDx is well-positioned for future growth. While the company faces risks related to market dependence, competition, and regulatory challenges, its strengths in innovation, market leadership, and global expansion provide a solid foundation for long-term success. As the demand for personalized medicine continues to grow, CareDx is poised to play a leading role in shaping the future of transplant care.